NBIX - Neurocrine Biosciences Inc

NBIX

$154.23 0.26 (-0.17%) Last updated: Aug 19, 2026 05:29

52-Week Range

$154.23

$122.14 $154.23 $186.12

Fundamentals Overview

Neurocrine Biosciences Inc is in the middle of its 52-week range, trading relatively flat today.

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell

Buy

Hold — 35% confidence Risk: Diversify and only invest what you can afford to lose.

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap

$15.70B

P/E (TTM)

N/A

EPS (TTM)

N/A

Dividend Yield

N/A

52-Week Range

$122.14 - $186.12

Volume vs Avg

N/A

About

Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candi...

Sector: stocks

Headquarters:

Website: www.neurocrine.com

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

Metric	Value
Valuation
P/E (TTM)	N/A
PEG (TTM)	N/A
P/B (TTM)	N/A
P/S (TTM)	N/A
Profitability
ROE (TTM)	N/A
ROA (TTM)	N/A
Revenue growth (YoY)	N/A
Net margin (TTM)	N/A
Debt to equity (TTM)	N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for NBIX.

Price target data is not available for this symbol from the current data source.

Stock Grades (Institutions)

No stock grades available for this symbol.

No price targets, ratings snapshot, or grades available for this symbol.